UA76405C2 - Use of purified ethyl ester of eicosapentenic acid for treating and preventing neurological disorders (variants) - Google Patents
Use of purified ethyl ester of eicosapentenic acid for treating and preventing neurological disorders (variants) Download PDFInfo
- Publication number
- UA76405C2 UA76405C2 UA2001085934A UA2001085934A UA76405C2 UA 76405 C2 UA76405 C2 UA 76405C2 UA 2001085934 A UA2001085934 A UA 2001085934A UA 2001085934 A UA2001085934 A UA 2001085934A UA 76405 C2 UA76405 C2 UA 76405C2
- Authority
- UA
- Ukraine
- Prior art keywords
- epa
- present
- drug
- use according
- composition
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 10
- 125000004494 ethyl ester group Chemical group 0.000 title abstract description 3
- 208000012902 Nervous system disease Diseases 0.000 title description 17
- 208000025966 Neurological disease Diseases 0.000 title description 16
- 239000003814 drug Substances 0.000 claims abstract description 90
- 229940079593 drug Drugs 0.000 claims abstract description 86
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 35
- 229930195729 fatty acid Natural products 0.000 claims abstract description 35
- 239000000194 fatty acid Substances 0.000 claims abstract description 35
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 35
- 208000035475 disorder Diseases 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 125
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 122
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 122
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 120
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims description 30
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims description 30
- 229960004170 clozapine Drugs 0.000 claims description 19
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 19
- 208000023105 Huntington disease Diseases 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 16
- 229960005017 olanzapine Drugs 0.000 claims description 15
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 15
- 230000004060 metabolic process Effects 0.000 claims description 9
- 102000004108 Neurotransmitter Receptors Human genes 0.000 claims description 8
- 108090000590 Neurotransmitter Receptors Proteins 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 229960003878 haloperidol Drugs 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 7
- 229960001534 risperidone Drugs 0.000 claims description 7
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 7
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 6
- 229960001076 chlorpromazine Drugs 0.000 claims description 6
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 229960000652 sertindole Drugs 0.000 claims description 6
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960000607 ziprasidone Drugs 0.000 claims description 6
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 6
- 229960004496 zotepine Drugs 0.000 claims description 6
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 6
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 5
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 5
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 abstract description 30
- 206010012289 Dementia Diseases 0.000 abstract description 21
- 208000020925 Bipolar disease Diseases 0.000 abstract description 15
- 208000019906 panic disease Diseases 0.000 abstract description 13
- 208000019901 Anxiety disease Diseases 0.000 abstract description 12
- 208000013403 hyperactivity Diseases 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
- 230000006735 deficit Effects 0.000 abstract description 2
- 208000020402 Enthesitis-related juvenile idiopathic arthritis Diseases 0.000 description 66
- 230000000694 effects Effects 0.000 description 41
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical group CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 38
- 208000020016 psychiatric disease Diseases 0.000 description 25
- 230000006378 damage Effects 0.000 description 21
- 229940114079 arachidonic acid Drugs 0.000 description 19
- 235000021342 arachidonic acid Nutrition 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 230000006872 improvement Effects 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 239000012528 membrane Substances 0.000 description 14
- 150000003904 phospholipids Chemical class 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 102000015439 Phospholipases Human genes 0.000 description 12
- 108010064785 Phospholipases Proteins 0.000 description 12
- 230000009471 action Effects 0.000 description 12
- 238000001994 activation Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 239000002858 neurotransmitter agent Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 230000019491 signal transduction Effects 0.000 description 12
- 208000018737 Parkinson disease Diseases 0.000 description 11
- 239000000935 antidepressant agent Substances 0.000 description 11
- 229940005513 antidepressants Drugs 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 206010033664 Panic attack Diseases 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 239000000164 antipsychotic agent Substances 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 206010003805 Autism Diseases 0.000 description 9
- 208000020706 Autistic disease Diseases 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 8
- 208000020401 Depressive disease Diseases 0.000 description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 8
- 230000036506 anxiety Effects 0.000 description 8
- 239000005516 coenzyme A Substances 0.000 description 8
- 229940093530 coenzyme a Drugs 0.000 description 8
- 235000021323 fish oil Nutrition 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical group CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 206010039424 Salivary hypersecretion Diseases 0.000 description 7
- 229940005529 antipsychotics Drugs 0.000 description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 7
- 208000004547 Hallucinations Diseases 0.000 description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
- 206010026749 Mania Diseases 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 208000027691 Conduct disease Diseases 0.000 description 5
- 206010022998 Irritability Diseases 0.000 description 5
- 208000008630 Sialorrhea Diseases 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- -1 inositol phosphates Chemical class 0.000 description 5
- XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 description 5
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 5
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical group O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 4
- 208000009829 Lewy Body Disease Diseases 0.000 description 4
- 201000002832 Lewy body dementia Diseases 0.000 description 4
- 208000016285 Movement disease Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 229940097320 beta blocking agent Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 4
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 4
- 229960004488 linolenic acid Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000000698 schizophrenic effect Effects 0.000 description 4
- 206010013954 Dysphoria Diseases 0.000 description 3
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 3
- 206010033864 Paranoia Diseases 0.000 description 3
- 208000027099 Paranoid disease Diseases 0.000 description 3
- 206010041250 Social phobia Diseases 0.000 description 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000002635 electroconvulsive therapy Methods 0.000 description 3
- 238000004710 electron pair approximation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003140 lateral ventricle Anatomy 0.000 description 3
- 229960001344 methylphenidate Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 208000022821 personality disease Diseases 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 229960004431 quetiapine Drugs 0.000 description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 108700016155 Acyl transferases Proteins 0.000 description 2
- 206010054196 Affect lability Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 206010027951 Mood swings Diseases 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 102000045404 acyltransferase activity proteins Human genes 0.000 description 2
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000002932 anti-schizophrenic effect Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000002641 lithium Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 208000022610 schizoaffective disease Diseases 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004940 sulpiride Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960002784 thioridazine Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 241000462296 Drugera Species 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000899793 Hypsophrys nicaraguensis Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 108010069175 acyl-CoA transferase Proteins 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- YEKFYCQGYMVFKR-UHFFFAOYSA-N docosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCC=CC=CC=CC=CC=CC(O)=O YEKFYCQGYMVFKR-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000020988 fatty fish Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 208000019016 inability to swallow Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940054010 other antipsychotics in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 229960000769 periciazine Drugs 0.000 description 1
- LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000002226 simultaneous effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9901809.5A GB9901809D0 (en) | 1999-01-27 | 1999-01-27 | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
PCT/GB2000/000164 WO2000044361A2 (en) | 1999-01-27 | 2000-01-21 | Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
UA76405C2 true UA76405C2 (en) | 2006-08-15 |
Family
ID=10846603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2001085934A UA76405C2 (en) | 1999-01-27 | 2000-01-21 | Use of purified ethyl ester of eicosapentenic acid for treating and preventing neurological disorders (variants) |
Country Status (34)
Country | Link |
---|---|
US (10) | US6384077B1 (zh) |
EP (2) | EP1148873B1 (zh) |
JP (1) | JP4959055B2 (zh) |
KR (1) | KR100760038B1 (zh) |
CN (2) | CN100423718C (zh) |
AT (1) | ATE300296T1 (zh) |
AU (1) | AU3065700A (zh) |
BR (1) | BR0007743A (zh) |
CA (1) | CA2360776C (zh) |
CZ (1) | CZ20012695A3 (zh) |
DE (1) | DE60021525T2 (zh) |
DK (1) | DK1148873T3 (zh) |
EE (1) | EE04629B1 (zh) |
ES (1) | ES2246825T3 (zh) |
GB (1) | GB9901809D0 (zh) |
HK (1) | HK1039564B (zh) |
HR (1) | HRP20010558A2 (zh) |
HU (1) | HU226713B1 (zh) |
IL (2) | IL144502A0 (zh) |
IS (1) | IS5988A (zh) |
MX (1) | MXPA01007662A (zh) |
MY (1) | MY136927A (zh) |
NO (1) | NO20013546L (zh) |
NZ (1) | NZ513172A (zh) |
PL (1) | PL199778B1 (zh) |
PT (1) | PT1148873E (zh) |
RS (1) | RS50133B (zh) |
RU (1) | RU2260423C2 (zh) |
SK (1) | SK10392001A3 (zh) |
TR (2) | TR200504156T2 (zh) |
TW (1) | TWI228041B (zh) |
UA (1) | UA76405C2 (zh) |
WO (1) | WO2000044361A2 (zh) |
ZA (1) | ZA200106105B (zh) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
EP1189662A1 (en) * | 1999-06-09 | 2002-03-27 | Eli Lilly And Company | Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist |
US6737078B1 (en) * | 1999-11-24 | 2004-05-18 | The Iams Company | Process for enhancing canine and feline reproductive performance |
GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
US20050032897A1 (en) * | 2000-11-22 | 2005-02-10 | The Iams Company | Process for enhancing canine and feline reproductive performance |
NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
GB0210212D0 (en) * | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
CA2485116C (en) * | 2002-05-03 | 2013-02-05 | Pronova Biocare As | Use of epa and dha in secondary prevention |
EP2295529B2 (en) * | 2002-07-11 | 2022-05-18 | Basf As | Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use |
SE0202188D0 (sv) * | 2002-07-11 | 2002-07-11 | Pronova Biocare As | A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
US7410663B2 (en) * | 2002-08-07 | 2008-08-12 | Kao Corporation | Oil or fat composition |
GB0221480D0 (en) * | 2002-09-16 | 2002-10-23 | Laxdale Ltd | Treatment of anorexia nervosa (AN) and bulimia |
GB0228079D0 (en) * | 2002-12-02 | 2003-01-08 | Laxdale Ltd | Huntington's Disease |
GB0301701D0 (en) * | 2003-01-24 | 2003-02-26 | Ensay Ltd | Psoriasis and Eicosapentaenoic acid |
GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
CH698539A8 (de) | 2003-08-18 | 2009-10-15 | Btg Int Ltd | Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose. |
US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
FR2860976B1 (fr) * | 2003-10-20 | 2006-02-10 | Ravi Shrivastava | Nouvelles compositions synergiques pour ameliorer la biodisponibilite et l'efficacite des acides gras polyinsatures pour le traitement des troubles du fonctionnement cerebral. |
WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
US6936598B2 (en) * | 2003-11-21 | 2005-08-30 | Hill's Pet Nutrition, Inc. | Composition and method |
US7754677B2 (en) * | 2003-12-05 | 2010-07-13 | Hill's Pet Nutrition, Inc. | Composition and method for reducing diarrhea in a mammal |
GB2409644B (en) * | 2003-12-31 | 2005-12-21 | Igennus Ltd | Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof |
ITMI20040069A1 (it) * | 2004-01-21 | 2004-04-21 | Tiberio Bruzzese | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
NZ553263A (en) | 2004-07-19 | 2010-06-25 | Biocon Ltd | Insulin-oligomer conjugates, formulations and uses thereof |
WO2006034361A2 (en) * | 2004-09-21 | 2006-03-30 | Ketocytonyx Inc. | Dopaminergic mimetics |
JP5491697B2 (ja) * | 2004-10-15 | 2014-05-14 | フォトンズ コーポレイション リミテッド | 高レベルオメガ−3および低レベル飽和脂肪酸を含む組成物 |
GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
WO2006077495A1 (en) * | 2005-01-24 | 2006-07-27 | Pronova Biocare As | Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases |
US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
AU2006242914B2 (en) * | 2005-05-04 | 2012-02-02 | Pronova Biopharma Norge As | New DHA derivatives and their use as medicaments |
CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
CA2570763C (en) | 2005-07-08 | 2011-08-23 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing onset of cardiovascular events |
CN103211807A (zh) * | 2005-07-08 | 2013-07-24 | Dsmip资产公司 | 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸 |
ITMI20051560A1 (it) * | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6 |
ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
WO2007071733A2 (en) | 2005-12-21 | 2007-06-28 | Brudy Technology, S.L. | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
PL2046312T3 (pl) * | 2006-07-14 | 2021-02-08 | Kaydence Pharma As | Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2 |
BRPI0717972A2 (pt) * | 2006-11-01 | 2013-11-12 | Pronova Biopharma Norge As | Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar) |
CN101535238A (zh) * | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
JP2010508262A (ja) * | 2006-11-01 | 2010-03-18 | プロノヴァ バイオファーマ ノルゲ アーエス | 組成物 |
KR101544584B1 (ko) * | 2006-11-01 | 2015-08-13 | 프로노바 바이오파마 너지 에이에스 | 오메가-3 지질 화합물 |
WO2008128166A1 (en) * | 2007-04-13 | 2008-10-23 | Concert Pharmaceuticals Inc. | Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds |
CA2639412A1 (en) | 2007-09-11 | 2009-03-11 | Universite Laval | Prostaglandin e2 modulation and uses thereof |
WO2009050738A2 (en) | 2007-10-16 | 2009-04-23 | Biocon Limited | An orally administerable solid pharmaceutical composition and a process thereof |
EP2217558A1 (en) * | 2007-10-31 | 2010-08-18 | Pronova Biopharma Norge AS | New dha derivatives and their use as medicaments |
US20090182049A1 (en) * | 2008-01-16 | 2009-07-16 | Joar Arild Opheim | Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans |
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
WO2010027266A1 (en) * | 2008-09-05 | 2010-03-11 | Van De Langenberg, Hendrikus Theodorus Ardina Hubertus | Means and methods for counteracting neurological disorders |
AU2015203289B2 (en) * | 2008-09-09 | 2017-03-16 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
US20110166229A1 (en) | 2008-09-09 | 2011-07-07 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
LT3037089T (lt) | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
JP6176894B2 (ja) | 2009-03-09 | 2017-08-09 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
GB0904300D0 (en) | 2009-03-12 | 2009-04-22 | Amarin Neuroscience Ltd | Essential fatty acid compounds |
AU2014203034B2 (en) * | 2009-04-29 | 2016-09-15 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
US8455472B2 (en) * | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
JP2011136948A (ja) * | 2009-12-28 | 2011-07-14 | Nisshin Oillio Group Ltd | うつ病又はうつ状態の予防又は治療用油脂組成物 |
WO2011087981A2 (en) * | 2010-01-15 | 2011-07-21 | E. I. Du Pont De Nemours And Company | Clinical benefits of eicosapentaenoic acid in humans |
RU2728825C2 (ru) * | 2010-03-04 | 2020-07-31 | Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания |
GB201020133D0 (en) * | 2010-11-26 | 2011-01-12 | Royal Holloway & Bedford New College | Therapeutic use of compounds |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
KR20140007430A (ko) * | 2011-02-11 | 2014-01-17 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 에이코사펜타엔산 농축물 |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US20120252888A1 (en) * | 2011-03-29 | 2012-10-04 | Palupa Medical Ltd. | Compositions and Methods for Treating Neurologic Disorders |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
WO2013142482A1 (en) | 2012-03-20 | 2013-09-26 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
RU2015102808A (ru) * | 2012-06-29 | 2016-08-20 | Амарин Фармасьютикалз Айрлэнд Лимитед | Способы лечения педиатрического метаболического синдрома |
US20150359773A1 (en) | 2012-09-26 | 2015-12-17 | Seth D. Feuerstein | Combination methods and compositions including sleep therapeutics for treating mood |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
CA2894366A1 (en) * | 2012-12-06 | 2014-06-12 | Matinas Biopharma, Inc. | Methods of administering compositions comprising docosapentaenoic acid |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US20150374660A1 (en) * | 2013-02-26 | 2015-12-31 | Jiva Pharma, Inc. | Ascorbate Esters of Omega-3 Fatty Acids and Their Formulations and Uses |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US9428711B2 (en) | 2013-05-07 | 2016-08-30 | Groupe Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
AU2014360255B2 (en) * | 2013-12-05 | 2017-07-27 | Enzymotec Ltd. | Serine glycerophospholipid preparation and method for treatment of seizures |
EP3118186B1 (fr) * | 2013-12-11 | 2022-02-09 | Novasep Process | Installation chromatographique de production d acides gras polyinsatures |
BR112016015718B1 (pt) | 2014-01-07 | 2021-12-07 | Novasep Process Solutions | Processo de purificação de aminoácidos aromáticos |
US9540307B2 (en) | 2014-05-08 | 2017-01-10 | Jiva Pharma, Inc. | Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
RU2582962C1 (ru) * | 2014-12-23 | 2016-04-27 | Ольга Алексеевна Громова | Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты) |
US10183044B2 (en) | 2015-05-15 | 2019-01-22 | P Tech, Llc | Systems and methods for thrombosis prevention |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11065288B2 (en) * | 2017-09-29 | 2021-07-20 | Kinjirushi Co., Ltd. | Neuron activator |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
WO2019241563A1 (en) | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for lowering triglyceride levels with a concentrated fish oil-based pharmaceutical composition |
CN108721269A (zh) * | 2018-07-10 | 2018-11-02 | 广东海洋大学 | 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用 |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
JP2023518640A (ja) * | 2020-01-29 | 2023-05-08 | ウニバシタット デ レス イレス バレアース | αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用 |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1021147A (en) * | 1972-10-30 | 1977-11-22 | Stephen S. Trond | Method for preparing oxysulfide phosphors with large particle size |
US4377526A (en) * | 1981-05-15 | 1983-03-22 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid and its esters |
US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
US4727340A (en) * | 1986-04-30 | 1988-02-23 | Tektronix, Inc. | Comb generators |
US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
US5252333A (en) | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
DE3719097C1 (de) * | 1987-06-06 | 1988-06-09 | Fratzer Uwe | Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
US4843095A (en) | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
CA1338683C (en) * | 1988-09-13 | 1996-10-29 | Efamol Holdings Plc | Fatty acid therapy and compositions |
GB2223943A (en) | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
JP2839276B2 (ja) * | 1989-01-23 | 1998-12-16 | 日本分光工業株式会社 | 超臨界流体抽出・分離方法及び装置 |
GB8906369D0 (en) * | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
JPH0358926A (ja) * | 1989-07-27 | 1991-03-14 | Taiyo Fishery Co Ltd | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
CA2043615C (en) * | 1990-06-04 | 2001-08-14 | Kazuhiko Hata | Method of producing eicosapentaenoic acid or the ester derivative thereof |
GB9012651D0 (en) * | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
JP3103588B2 (ja) * | 1990-11-16 | 2000-10-30 | 持田製薬株式会社 | リポプロテイン(a)低下剤 |
SE9101642D0 (sv) | 1991-05-30 | 1991-05-30 | Kabi Pharmacia Ab | Phospholipids |
US5215630A (en) * | 1991-06-04 | 1993-06-01 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation |
DE4133694C2 (de) * | 1991-10-11 | 1993-10-07 | Fresenius Ag | Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen |
JP3400466B2 (ja) | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | 高純度エイコサペンタエン酸またはそのエステルの製造方法 |
JPH0649479A (ja) * | 1992-07-28 | 1994-02-22 | Maruha Corp | ω−3不飽和脂肪酸系化合物の安定化法 |
US5516801A (en) * | 1992-08-21 | 1996-05-14 | Scotia Holdings Plc | Fatty acid treatment for ectopic calcium deposition |
GB9217780D0 (en) * | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
US5888541A (en) * | 1992-08-21 | 1999-03-30 | Scotia Holdings Plc | Fatty acid treatment |
GB9300125D0 (en) * | 1993-01-06 | 1993-03-03 | Scotia Holdings Plc | Compositions containing esters of unsaturated fatty acids |
AU7053494A (en) | 1993-06-04 | 1995-01-03 | Martek Biosciences Corporation | Method of treating coronary vascular disease using docosahexaenoic acid |
GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
US5760081A (en) * | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
AU711482B2 (en) * | 1994-06-28 | 1999-10-14 | Scotia Holdings Plc | Compositions for treatment of diabetic complications |
IT1274734B (it) * | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
JP3552810B2 (ja) | 1995-09-27 | 2004-08-11 | 松下電器産業株式会社 | 部品供給部の部品一括交換方法と装置 |
GB9519661D0 (en) * | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
AU2738497A (en) * | 1996-04-24 | 1997-11-12 | Brigham And Women's Hospital | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder |
US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
US20020055539A1 (en) * | 1996-10-02 | 2002-05-09 | Bockow Barry I. | Compositions and methods for treating cardiovascular conditions |
KR20060061409A (ko) * | 1996-10-11 | 2006-06-07 | 스카리스타 리미티드 | 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일 |
KR100569319B1 (ko) * | 1997-10-30 | 2006-04-07 | 모리시타 진탄 가부시키가이샤 | 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법 |
DE69842121D1 (de) * | 1997-12-10 | 2011-03-17 | Cyclosporine Therapeutics Ltd | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen |
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US6193999B1 (en) * | 1999-03-01 | 2001-02-27 | Banner Pharmacaps, Inc. | Gum acacia substituted soft gelatin capsules |
ATE394941T1 (de) * | 1999-07-28 | 2008-05-15 | Swiss Caps Rechte & Lizenzen | Präparat zur verwendung als medikament und/oder nahrungsmittelergänzung |
WO2001015552A1 (en) | 1999-08-30 | 2001-03-08 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
DK1157692T3 (da) | 2000-05-22 | 2006-02-06 | Pro Aparts Investimentos E Con | Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf |
GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
GB0111282D0 (en) | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
PT1390025E (pt) * | 2001-05-30 | 2005-08-31 | Laxdale Ltd | Utilizacao de coenzima q (ubiquinona) e acido eicosapentaenoico (epa) para o tratamento de linfoma nao de hodgkin e de distubios psiquiatricos ou neurologicos |
ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
ITMI20020269A1 (it) | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
US20030166614A1 (en) * | 2002-03-01 | 2003-09-04 | Harrison Stanley F. | Method for reducing cholesterol and triglycerides |
US20070087137A9 (en) * | 2003-06-26 | 2007-04-19 | Elwakil Hamdy A | Decorative laminated safety glass |
US7314643B2 (en) * | 2002-08-20 | 2008-01-01 | Nikken Chemicals Co., Ltd. | Soft capsule preparation |
KR100539027B1 (ko) | 2002-10-18 | 2005-12-26 | 현대모비스 주식회사 | 차량의 조향각 검출 장치 |
TW200418957A (en) * | 2002-11-22 | 2004-10-01 | Nippon Suisan Kaiaha Ltd | Compositions for external use containing polyunsaturated fatty acids salts thereof or esters thereof and method of manufacturing the same |
CN1756545A (zh) | 2003-03-05 | 2006-04-05 | 索尔瓦药物有限公司 | ω-3-脂肪酸在治疗糖尿病患者中的应用 |
GB2409644B (en) * | 2003-12-31 | 2005-12-21 | Igennus Ltd | Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof |
CA2589654C (en) * | 2004-12-06 | 2016-02-16 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
US20070191467A1 (en) * | 2004-12-06 | 2007-08-16 | Reliant Pharmaceutical, Inc. | Statin and omega-3 fatty acids for lipid therapy |
US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
US7628027B2 (en) | 2005-07-19 | 2009-12-08 | Hussmann Corporation | Refrigeration system with mechanical subcooling |
ITMI20051560A1 (it) | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6 |
US20070104779A1 (en) * | 2005-11-07 | 2007-05-10 | Rongen Roelof M | Treatment with omega-3 fatty acids and products thereof |
CA2634139C (en) * | 2005-12-20 | 2015-06-23 | Cenestra, Llc. | Omega 3 fatty acid formulations |
CN101365438A (zh) * | 2006-02-07 | 2009-02-11 | 持田制药株式会社 | 预防中风复发的组合物 |
US20090304784A1 (en) * | 2006-07-28 | 2009-12-10 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
LT3037089T (lt) * | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
US8455472B2 (en) * | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
WO2013192109A1 (en) * | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
-
1999
- 1999-01-27 GB GBGB9901809.5A patent/GB9901809D0/en not_active Ceased
-
2000
- 2000-01-21 CN CNB008032025A patent/CN100423718C/zh not_active Expired - Fee Related
- 2000-01-21 WO PCT/GB2000/000164 patent/WO2000044361A2/en not_active Application Discontinuation
- 2000-01-21 SK SK1039-2001A patent/SK10392001A3/sk unknown
- 2000-01-21 DK DK00900733T patent/DK1148873T3/da active
- 2000-01-21 CZ CZ20012695A patent/CZ20012695A3/cs unknown
- 2000-01-21 PL PL349718A patent/PL199778B1/pl not_active IP Right Cessation
- 2000-01-21 AU AU30657/00A patent/AU3065700A/en not_active Abandoned
- 2000-01-21 EE EEP200100387A patent/EE04629B1/xx not_active IP Right Cessation
- 2000-01-21 EP EP00900733A patent/EP1148873B1/en not_active Expired - Lifetime
- 2000-01-21 EP EP03079169A patent/EP1417963A1/en not_active Ceased
- 2000-01-21 BR BR0007743-7A patent/BR0007743A/pt active Pending
- 2000-01-21 PT PT00900733T patent/PT1148873E/pt unknown
- 2000-01-21 TR TR2005/04156T patent/TR200504156T2/xx unknown
- 2000-01-21 MX MXPA01007662A patent/MXPA01007662A/es not_active IP Right Cessation
- 2000-01-21 NZ NZ513172A patent/NZ513172A/en not_active IP Right Cessation
- 2000-01-21 RU RU2001121185/14A patent/RU2260423C2/ru not_active IP Right Cessation
- 2000-01-21 DE DE60021525T patent/DE60021525T2/de not_active Expired - Lifetime
- 2000-01-21 CA CA002360776A patent/CA2360776C/en not_active Expired - Fee Related
- 2000-01-21 HU HU0105215A patent/HU226713B1/hu not_active IP Right Cessation
- 2000-01-21 CN CNA2005101097522A patent/CN1739496A/zh active Pending
- 2000-01-21 IL IL14450200A patent/IL144502A0/xx active IP Right Grant
- 2000-01-21 RS YUP-542/01A patent/RS50133B/sr unknown
- 2000-01-21 JP JP2000595665A patent/JP4959055B2/ja not_active Expired - Fee Related
- 2000-01-21 ES ES00900733T patent/ES2246825T3/es not_active Expired - Lifetime
- 2000-01-21 TR TR2001/02170T patent/TR200102170T2/xx unknown
- 2000-01-21 AT AT00900733T patent/ATE300296T1/de active
- 2000-01-21 KR KR1020017009388A patent/KR100760038B1/ko not_active IP Right Cessation
- 2000-01-21 UA UA2001085934A patent/UA76405C2/uk unknown
- 2000-01-26 MY MYPI20000272A patent/MY136927A/en unknown
- 2000-01-27 US US09/492,741 patent/US6384077B1/en not_active Expired - Lifetime
- 2000-03-07 TW TW089101385A patent/TWI228041B/zh active
-
2001
- 2001-06-29 IS IS5988A patent/IS5988A/is unknown
- 2001-07-17 NO NO20013546A patent/NO20013546L/no not_active Application Discontinuation
- 2001-07-23 IL IL144502A patent/IL144502A/en not_active IP Right Cessation
- 2001-07-25 HR HR20010558A patent/HRP20010558A2/hr not_active Application Discontinuation
- 2001-07-25 ZA ZA200106105A patent/ZA200106105B/xx unknown
- 2001-12-14 US US10/014,603 patent/US6689812B2/en not_active Expired - Lifetime
-
2002
- 2002-01-29 HK HK02100688.5A patent/HK1039564B/zh not_active IP Right Cessation
- 2002-06-19 US US10/173,622 patent/US20020183389A1/en not_active Abandoned
- 2002-07-10 US US10/191,430 patent/US7119118B2/en not_active Expired - Fee Related
-
2004
- 2004-02-12 US US10/776,226 patent/US20040162348A1/en not_active Abandoned
-
2006
- 2006-02-24 US US11/361,069 patent/US20060252833A1/en not_active Abandoned
-
2008
- 2008-03-20 US US12/052,598 patent/US8188146B2/en not_active Expired - Fee Related
-
2010
- 2010-11-22 US US12/951,620 patent/US20110065793A1/en not_active Abandoned
-
2012
- 2012-04-04 US US13/439,392 patent/US20120195963A1/en not_active Abandoned
-
2013
- 2013-09-16 US US14/028,451 patent/US20140073692A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA76405C2 (en) | Use of purified ethyl ester of eicosapentenic acid for treating and preventing neurological disorders (variants) | |
JP6092843B2 (ja) | 神経障害の治療用組成物 | |
JP2007518764A (ja) | 中枢神経系障害の治療のための、選択されたn−3系脂肪酸の高度濃縮組成物の使用 | |
JP5043677B2 (ja) | アルツハイマー型認知症予防・治療剤 | |
AU2006201772B2 (en) | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders | |
AU2004235641B2 (en) | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders | |
CA2545190A1 (en) | Agent for preventing and treating language disorders |